Research overview
BPC-157 supplied as a 5mg unit of metabolic pathway research-grade peptide. For research use only.
Research context
BPC-157 is a well-characterized peptide in metabolic pathway research. This lot is analytically verified to ≥99% purity by HPLC and confirmed by mass-spectrometric identity testing. Independent third-party certificates of analysis are available on request for every production run.
Handling & reconstitution
Store unopened vials refrigerated at 2–8°C. Reconstitute with sterile bacteriostatic water and store reconstituted material at 2–8°C for research use. Avoid repeated freeze-thaw cycles. Record lot number and reconstitution date in your research log.
Regulatory
For research and analytical use only. Not for human or veterinary administration. Arkon is not a compounding pharmacy. Purchase is restricted to verified research providers.
| Purity | 99% |
|---|
| Third-party tested | ✓ Yes |
|---|
| Form | Lyophilized Vials |
|---|
| Strength | 5mg |
|---|
Storage & reconstitution
- Storage (lyophilized): −20°C, protected from light. Stable until labeled expiry.
- Storage (reconstituted): 2–8°C, use within 30 days; do not freeze/thaw repeatedly.
- Reconstitution diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard. Sterile saline is acceptable for short-term studies.
- Aliquoting: divide into single-use volumes immediately after reconstitution to minimize freeze/thaw cycles.
- Documentation: retain certificate of analysis (COA) for batch traceability.
Final handling guidance is product-specific and is supplied with each shipment.
Regulatory disclosures
Arkon products are intended for research and analytical use only. They are not for human or veterinary administration, are not therapeutics, and are not for use as a food, drug, cosmetic, or household chemical.
Purchase is restricted to verified licensed practitioners and qualified research institutions. Verification uses the National Provider Identifier (NPI) registry and state-issued license number.
Compounds in the catalog have not been evaluated by the FDA. Any clinical or off-label use is the responsibility of the licensed practitioner.
For controlled-substance scheduled compounds, a current DEA registration is required at point of order.
Final regulatory wording is undergoing legal review. The text above is the current placeholder posture.
